Mediation of in vitro cytochrome P450 activity by common pharmaceutical excipients

Molecular Pharmaceutics

Volumn 10, Issue 7, 2013, Pages 2739-2748

  Martin, Philip ^a   Giardiello, Marco ^a   McDonald, Tom O ^a   Rannard, Steven P ^a   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

clearance; excipients; formulation; inactive ingredients; metabolism; pharmacokinetics

Indexed keywords

CYTOCHROME P450; EXCIPIENT; ISOENZYME;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; PRIORITY JOURNAL;

CYTOCHROME P-450 ENZYME SYSTEM; EXCIPIENTS; MODELS, THEORETICAL; OXIDATION-REDUCTION; POLYMERS; SURFACE-ACTIVE AGENTS;

EID: 84879725408     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400175n     Document Type: Article

References (48)

1. Huang, W. X.; Desai, M.; Tang, Q.; Yang, R.; Vivilecchia, R. V.; Joshi, Y. Elimination of metformin-croscarmellose sodium interaction by competition Int. J. Pharm. 2006, 311 (1-2) 33-9
2. Cornaire, G.; Woodley, J.; Hermann, P.; Cloarec, A.; Arellano, C.; Houin, G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo Int. J. Pharm. 2004, 278 (1) 119-31
3. Buggins, T. R.; Dickinson, P. A.; Taylor, G. The effects of pharmaceutical excipients on drug disposition Adv. Drug Delivery Rev. 2007, 59 (15) 1482-503
4. Hanke, U.; May, K.; Rozehnal, V.; Nagel, S.; Siegmund, W.; Weitschies, W. Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2) Eur. J. Pharm. Biopharm. 2010, 76 (2) 260-8
5. Lennernas, H.; Abrahamsson, B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension J. Pharm. Pharmacol. 2005, 57 (3) 273-85
6. Strickley, R. G. Solubilizing excipients in oral and injectable formulations Pharm. Res. 2004, 21 (2) 201-30
7. Porter, C. J.; Trevaskis, N. L.; Charman, W. N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discovery 2007, 6 (3) 231-48
8. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2000, 44 (1) 235-49
9. Ren, X.; Mao, X.; Si, L.; Cao, L.; Xiong, H.; Qiu, J.; Schimmer, A. D.; Li, G. Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration Eur. J. Pharm. Biopharm. 2008, 70 (1) 279-88
10. Wienkers, L. C.; Heath, T. G. Predicting in vivo drug interactions from in vitro drug discovery data Nat. Rev. Drug Discovery 2005, 4 (10) 825-33
11. Nebert, D. W.; Russell, D. W. Clinical importance of the cytochromes P450 Lancet 2002, 360 (9340) 1155-62
12. Lewis, D. F. 57 varieties: the human cytochromes P450 Pharmacogenomics 2004, 5 (3) 305-18
13. Yan, Z.; Caldwell, G. W. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery Curr. Top. Med. Chem. 2001, 1 (5) 403-25
14. Slaughter, R. L.; Edwards, D. J. Recent advances: the cytochrome P450 enzymes Ann. Pharmacother. 1995, 29 (6) 619-24
15. Zhang, Q. Y.; Dunbar, D.; Ostrowska, A.; Zeisloft, S.; Yang, J.; Kaminsky, L. S. Characterization of human small intestinal cytochromes P-450 Drug Metab. Dispos. 1999, 27 (7) 804-9
16. van Herwaarden, A. E.; van Waterschoot, R. A.; Schinkel, A. H. How important is intestinal cytochrome P450 3A metabolism? Trends Pharmacol. Sci. 2009, 30 (5) 223-7
17. Paine, M. F.; Hart, H. L.; Ludington, S. S.; Haining, R. L.; Rettie, A. E.; Zeldin, D. C. The human intestinal cytochrome P450 "pie" Drug Metab. Dispos. 2006, 34 (5) 880-6
18. Paine, M. F.; Khalighi, M.; Fisher, J. M.; Shen, D. D.; Kunze, K. L.; Marsh, C. L.; Perkins, J. D.; Thummel, K. E. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J. Pharmacol. Exp. Ther. 1997, 283 (3) 1552-62
19. Koch, I.; Weil, R.; Wolbold, R.; Brockmoller, J.; Hustert, E.; Burk, O.; Nuessler, A.; Neuhaus, P.; Eichelbaum, M.; Zanger, U.; Wojnowski, L. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA Drug Metab. Dispos. 2002, 30 (10) 1108-14
20. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P. B.; Daly, A.; Wrighton, S. A.; Hall, S. D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M. S.; Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat. Genet. 2001, 27 (4) 383-91
21. Soars, M. G.; Grime, K.; Riley, R. J. Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5 Xenobiotica 2006, 36 (4) 287-99
22. Lieber, C. S. Cytochrome P-4502E1: its physiological and pathological role Physiol. Rev. 1997, 77 (2) 517-44
23. Lieber, C. S. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)-a review Alcohol.: Clin. Exp. Res. 1999, 23 (6) 991-1007
24. Leclercq, I. A.; Farrell, G. C.; Field, J.; Bell, D. R.; Gonzalez, F. J.; Robertson, G. R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis J. Clin. Invest. 2000, 105 (8) 1067-75
25. Kim, S. N.; Seo, J. Y.; Jung da, W.; Lee, M. Y.; Jung, Y. S.; Kim, Y. C. Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation Drug Metab. Dispos. 2007, 35 (10) 1754-8
26. Yang, C. S.; Yoo, J. S.; Ishizaki, H.; Hong, J. Y. Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation Drug Metab. Rev. 1990, 22 (2-3) 147-59
27. Ebrahim Attia, A. B.; Ong, Z. Y.; Hedrick, J. L.; Lee, P. P.; Ee, P. L. R.; Hammond, P. T.; Yang, Y.-Y. Mixed micelles self-assembled from block copolymers for drug delivery Curr. Opin. Colloid Interface Sci. 2011, 16 (3) 182-194
28. Yuichi Ohya, A. T.; Nagahama, K. Biodegradable Polymeric Assemblies for Biomedical Materials Polym. Nanomed. 2012, 247, 65-114
29. Pearson, R. M.; Sunoqrot, S.; Hsu, H. J.; Bae, J. W.; Hong, S. Dendritic nanoparticles: the next generation of nanocarriers? Ther. Delivery 2012, 3 (8) 941-59
30. Seyednejad, H.; Ghassemi, A. H.; van Nostrum, C. F.; Vermonden, T.; Hennink, W. E. Functional aliphatic polyesters for biomedical and pharmaceutical applications J. Controlled Release 2011, 152 (1) 168-76
31. Larson, N.; Ghandehari, H. Polymeric Conjugates for Drug Delivery Chem. Mater. 2012, 24 (5) 840-53
32. Kalasz, H.; Antal, I. Drug Excipients Curr. Med. Chem. 2006, 13 (21) 2535-63
33. Giannattasio, F.; Salvio, A.; Varriale, M.; Picciotto, F. P.; Di Costanzo, G. G.; Visconti, M. Three cases of severe acute hepatitis after parenteral administration of amiodarone: the active ingredient is not the only agent responsible for hepatotoxicity Ann. Ital. Med. Interna 2002, 17 (3) 180-4
34. Hirama, S.; Tatsuishi, T.; Iwase, K.; Nakao, H.; Umebayashi, C.; Nishizaki, Y.; Kobayashi, M.; Ishida, S.; Okano, Y.; Oyama, Y. Flow-cytometric analysis on adverse effects of polysorbate 80 in rat thymocytes Toxicology 2004, 199 (2-3) 137-43
35. Shayeganpour, A.; El-Kadi, A. O.; Brocks, D. R. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: the contribution of cytochrome P450 3A isoforms Drug Metab. Dispos. 2006, 34 (1) 43-50
36. Leung, H. W.; Ballantyne, B. Evaluation of the genotoxic potential of alkylalkanolamines Mutat. Res. 1997, 393 (1-2) 7-15
37. Landes, N.; Pfluger, P.; Kluth, D.; Birringer, M.; Ruhl, R.; Bol, G. F.; Glatt, H.; Brigelius-Flohe, R. Vitamin E activates gene expression via the pregnane X receptor Biochem. Pharmacol. 2003, 65 (2) 269-73
38. Isin, E. M.; Sohl, C. D.; Eoff, R. L.; Guengerich, F. P. Cooperativity of cytochrome P450 1A2: interactions of 1,4-phenylene diisocyanide and 1-isopropoxy-4-nitrobenzene Arch. Biochem. Biophys. 2008, 473 (1) 69-75
39. Isin, E. M.; Guengerich, F. P. Substrate binding to cytochromes P450 Anal. Bioanal. Chem. 2008, 392 (6) 1019-30
40. Anzenbacher, P.; Otyepka, M. Editorial: cytochromes P450: flexibility and plasticity-properties determining substrate preferences Curr. Drug Metab. 2012, 13 (2) 129
41. Zanger, U. M.; Raimundo, S.; Eichelbaum, M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 369 (1) 23-37
42. Hong, J. Y.; Yang, C. S.; Lee, M.; Wang, Y. Y.; Huang, W. Q.; Tan, Y.; Patten, C. J.; Bondoc, F. Y. Role of cytochromes P450 in the metabolism of methyl tert-butyl ether in human livers Arch. Toxicol. 1997, 71 (4) 266-9
43. Wijnen, P. A.; Op den Buijsch, R. A.; Drent, M.; Kuijpers, P. M.; Neef, C.; Bast, A.; Bekers, O.; Koek, G. H. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms Aliment. Pharmacol. Ther. 2007, 26 (Suppl. 2) 211-9
44. Rettie, A. E.; Korzekwa, K. R.; Kunze, K. L.; Lawrence, R. F.; Eddy, A. C.; Aoyama, T.; Gelboin, H. V.; Gonzalez, F. J.; Trager, W. F. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions Chem. Res. Toxicol. 1992, 5 (1) 54-9
45. Veronese, M. E.; Mackenzie, P. I.; Doecke, C. J.; McManus, M. E.; Miners, J. O.; Birkett, D. J. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9 Biochem. Biophys. Res. Commun. 1991, 175 (3) 1112-8
46. Miners, J. O.; Birkett, D. J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism Br. J. Clin. Pharmacol. 1998, 45 (6) 525-38
47. Hutzler, J. M.; Kolwankar, D.; Hummel, M. A.; Tracy, T. S. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements Drug Metab. Dispos. 2002, 30 (11) 1194-200
48. Hutzler, J. M.; Hauer, M. J.; Tracy, T. S. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model Drug Metab. Dispos. 2001, 29 (7) 1029-34